Centre for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston 02115, MA, USA.
Trends Mol Med. 2013 Feb;19(2):108-16. doi: 10.1016/j.molmed.2012.12.002. Epub 2013 Jan 7.
Inflammation has a central role in cancer progression. Metastatic tumors arise at sites of chronic inflammation, and tumors or tumor-infiltrating immune cells produce inflammatory mediators. By contrast, natural killer (NK) cells and cytotoxic T cells (CTLs) help eliminate premalignant lesions and limit the rate of tumor metastasis. Interleukin (IL)-27 is an IL-12 family cytokine chiefly produced by antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages, and alone or in combination with other cytokines, IL-27 boosts antitumor immunity by contributing to the development of NK cells and CTLs - a central immnunomodulatory effect - and by exerting potent antiangiogenic and antimetastatic activities, a local antitumor effect. In this review, we argue that by virtue of its rate-limiting functions in innate and adaptive immune responses, modulating IL-27 holds considerable promise for future cancer immunotherapy.
炎症在癌症进展中起着核心作用。转移性肿瘤出现在慢性炎症部位，肿瘤或肿瘤浸润免疫细胞产生炎症介质。相比之下，自然杀伤 (NK) 细胞和细胞毒性 T 细胞 (CTL) 有助于消除癌前病变并限制肿瘤转移的速度。白细胞介素 (IL)-27 是一种主要由抗原呈递细胞 (APC) 如树突状细胞 (DC) 和巨噬细胞产生的 IL-12 家族细胞因子，单独或与其他细胞因子联合使用，通过促进 NK 细胞和 CTL 的发育，IL-27 增强抗肿瘤免疫——这是一种主要的免疫调节作用——并发挥强大的抗血管生成和抗转移活性，具有局部抗肿瘤作用。在这篇综述中，我们认为，由于其在固有和适应性免疫反应中的限速作用，调节 IL-27 为未来的癌症免疫治疗提供了巨大的希望。
